Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit [Yahoo! Finance]
Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit
Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium
Artelo Biosciences, Inc. (NASDAQ: ARTL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Artelo Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update